J&J (JNJ - Free Report) kicked off the fourth-quarter earnings season for the pharma sector with a beat. Sanofi (SNY - Free Report) announced a deal to acquire Inhibrx’s (INBX - Free Report) pipeline candidate, INBRX-101, for an aggregate transaction value of nearly $2.2 billion. Ionis (IONS - Free Report) announced positive top-line data from a phase III study evaluating its pipeline candidate, donidalorsen, for treating hereditary angioedema (HAE), a rare and life-threatening genetic disease.
Recap of the Week’s Most Important Stories
J&J Begins Q4 Earnings Season: J&J reported strong fourth-quarter results, beating estimates for earnings as well as sales. Its Innovative Medicines unit outperformed expectations, with sales of several key drugs like Darzalex, Stelara, Tremfya and Imbruvica beating estimates. The MedTech segment also beat the Zacks Consensus Estimate. Sales of J&J’s Innovative Medicines segment rose 4% on an operational basis, while that of the MedTech segment rose 13.4%.
J&J re-confirmed its full-year adjusted earnings and sales growth guidance that it had issued in December. For 2024, J&J expects total revenues in the range of $87.8 billion-$88.6 billion, which implies growth in the range of 4.5%-5.5%, driven by its Innovative Medicine and MedTech segments. The company maintained its operational sales growth guidance in the range of 5-6% and also its adjusted earnings per share guidance in the range of $10.55-$10.75. The earnings range implies growth in the range of 6.4%-8.4%.
Sanofi to Buy Inhibrx: Sanofi announced a definitive agreement to acquire INBRX-101, a rare disease pipeline candidate, from Inhibrx following the spin-off of non-INBRX-101 assets into a new publicly traded company called New Inhibrx. INBRX-101 is being developed in a phase II study to treat alpha-1 antitrypsin deficiency, an inherited rare disease characterized by low levels of AAT protein, which mainly affects lung function.
For the merger agreement, shareholders of Inhibrx will receive a consideration of $30 per share in cash plus a contingent value right equal to $5 per share plus 0.25 shares in New Inhibrx. In addition, Sanofi has agreed to pay off Inhibrx's outstanding debt balance and will also capitalize New Inhibrx with $200 million in cash. Sanofi will have an equity stake of 8% in New Inhibrx. All these add up to an aggregate transaction value of $2.2 billion. The transaction has been approved by the board of directors of both companies and is expected to be closed in the second quarter of 2024.
Ionis’ Donidalorsen Meets Goal in HAE Study: Ionis’ phase III study evaluating its pipeline candidate donidalorsen for treating HAE achieved its primary endpoint. The OASIS-HAE study showed a statistically significant reduction in the rate of angioedema attacks in patients treated with donidalorsen every four weeks or patients treated every eight weeks, compared to placebo. In addition, donidalorsen achieved statistical significance on all secondary endpoints in the 4-week arm and key secondary endpoints in the 8-week arm. Based on these results, Ionis plans to file a new drug application for donidalorsen with the FDA. Ionis’ partner, Otsuka, is also looking to file a marketing authorization application in Europe.
The NYSE ARCA Pharmaceutical Index declined 0.19% in the last five trading sessions.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
J&J (JNJ - Free Report) kicked off the fourth-quarter earnings season for the pharma sector with a beat. Sanofi (SNY - Free Report) announced a deal to acquire Inhibrx’s (INBX - Free Report) pipeline candidate, INBRX-101, for an aggregate transaction value of nearly $2.2 billion. Ionis (IONS - Free Report) announced positive top-line data from a phase III study evaluating its pipeline candidate, donidalorsen, for treating hereditary angioedema (HAE), a rare and life-threatening genetic disease.
Recap of the Week’s Most Important Stories
J&J Begins Q4 Earnings Season: J&J reported strong fourth-quarter results, beating estimates for earnings as well as sales. Its Innovative Medicines unit outperformed expectations, with sales of several key drugs like Darzalex, Stelara, Tremfya and Imbruvica beating estimates. The MedTech segment also beat the Zacks Consensus Estimate. Sales of J&J’s Innovative Medicines segment rose 4% on an operational basis, while that of the MedTech segment rose 13.4%.
J&J re-confirmed its full-year adjusted earnings and sales growth guidance that it had issued in December. For 2024, J&J expects total revenues in the range of $87.8 billion-$88.6 billion, which implies growth in the range of 4.5%-5.5%, driven by its Innovative Medicine and MedTech segments. The company maintained its operational sales growth guidance in the range of 5-6% and also its adjusted earnings per share guidance in the range of $10.55-$10.75. The earnings range implies growth in the range of 6.4%-8.4%.
Sanofi to Buy Inhibrx: Sanofi announced a definitive agreement to acquire INBRX-101, a rare disease pipeline candidate, from Inhibrx following the spin-off of non-INBRX-101 assets into a new publicly traded company called New Inhibrx. INBRX-101 is being developed in a phase II study to treat alpha-1 antitrypsin deficiency, an inherited rare disease characterized by low levels of AAT protein, which mainly affects lung function.
For the merger agreement, shareholders of Inhibrx will receive a consideration of $30 per share in cash plus a contingent value right equal to $5 per share plus 0.25 shares in New Inhibrx. In addition, Sanofi has agreed to pay off Inhibrx's outstanding debt balance and will also capitalize New Inhibrx with $200 million in cash. Sanofi will have an equity stake of 8% in New Inhibrx. All these add up to an aggregate transaction value of $2.2 billion. The transaction has been approved by the board of directors of both companies and is expected to be closed in the second quarter of 2024.
Ionis’ Donidalorsen Meets Goal in HAE Study: Ionis’ phase III study evaluating its pipeline candidate donidalorsen for treating HAE achieved its primary endpoint. The OASIS-HAE study showed a statistically significant reduction in the rate of angioedema attacks in patients treated with donidalorsen every four weeks or patients treated every eight weeks, compared to placebo. In addition, donidalorsen achieved statistical significance on all secondary endpoints in the 4-week arm and key secondary endpoints in the 8-week arm. Based on these results, Ionis plans to file a new drug application for donidalorsen with the FDA. Ionis’ partner, Otsuka, is also looking to file a marketing authorization application in Europe.
The NYSE ARCA Pharmaceutical Index declined 0.19% in the last five trading sessions.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on SNY - FREE
Get the latest research report on JNJ - FREE
Get the latest research report on IONS - FREE
Get the latest research report on INBX - FREE